Pharmacokinetics and pharmacodynamics of a single dose of sustained-release azithromycin formulation in pigeons.

To date, only a few studies on the azithromycin (AZM) pharmacokinetics in ornamental birds have been published. In the current study AZM concentrations in domestic pigeon (Columba livia domestica) plasma samples were analyzed using a validated ultra-high performance liquid chromatography tandem mass spectrometry method. The aim of the current study was to carry out an analysis of the pharmacokinetics and pharmacodynamics after administration of a single oral dose of a sustained-release AZM formulation and to conduct a simulation of treatment based on selected minimal inhibitory values. The study was performed with 12 healthy adult pigeons, both sexes. The pigeons tolerated AZM very well and no adverse effects were observed in any animal during the study. Based on the observed characteristics of the pharmacokinetics/ /pharmacodynamics profiles of AZM in pigeons, it should be noted that 35 mg/kg per os as a single starting dose and 25 mg/kg every 24 h are recommended for treatment of both suscep- tible and less susceptible pathogens.

[1]  T. Grabowski,et al.  Impact of milk yield on pharmacokinetics of six intramammary drugs - a population approach. , 2018, Polish journal of veterinary sciences.

[2]  M. Lomuto,et al.  First report of Coxiella burnetii and Borrelia burgdorferi sensu lato in poultry red mites, Dermanyssus gallinae (Mesostigmata, Acari), related to urban outbreaks of dermatitis in Italy , 2018, New microbes and new infections.

[3]  Jianchao Wei,et al.  Antimicrobial Resistance of Campylobacter Species Isolated from Broilers in Live Bird Markets in Shanghai, China. , 2017, Foodborne pathogens and disease.

[4]  K. Bobrek,et al.  Erysipelas Outbreaks in Flocks of Geese in Poland—Biochemical and Genetic Analyses of the Isolates , 2015, Avian diseases.

[5]  M. Fakhr,et al.  Prevalence and Antimicrobial Susceptibility of Campylobacter spp. in Oklahoma Conventional and Organic Retail Poultry , 2014, The open microbiology journal.

[6]  M. Britzi,et al.  Azithromycin pharmacokinetics in the serum and its distribution to the skin in healthy dogs and dogs with pyoderma. , 2014, Veterinary journal.

[7]  K. Brouwer,et al.  Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults , 2014, CPT: pharmacometrics & systems pharmacology.

[8]  R. Mullangi,et al.  A concise review of HPLC, LC-MS and LC-MS/MS methods for determination of azithromycin in various biological matrices. , 2013, Biomedical chromatography : BMC.

[9]  M. Sparo,et al.  Comparative Plasma Exposure and Lung Distribution of Two Human Use Commercial Azithromycin Formulations Assessed in Murine Model: A Preclinical Study , 2013, BioMed research international.

[10]  W. D. Wilson,et al.  Pharmacokinetics and preliminary safety evaluation of azithromycin in adult horses. , 2012, Journal of veterinary pharmacology and therapeutics.

[11]  A. J. Hulbert,et al.  The Long Life of Birds: The Rat-Pigeon Comparison Revisited , 2011, PloS one.

[12]  T. Tully,et al.  Evaluating 21-day Doxycycline and Azithromycin Treatments for Experimental Chlamydophila psittaci Infection in Cockatiels (Nymphicus hollandicus) , 2010, Journal of avian medicine and surgery.

[13]  T. Morris,et al.  Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria , 2009, Antimicrobial Agents and Chemotherapy.

[14]  D. Payne,et al.  Selection of Retapamulin, a Novel Pleuromutilin for Topical Use , 2006, Antimicrobial Agents and Chemotherapy.

[15]  J. W. Carpenter,et al.  PHARMACOKINETICS OF AZITHROMYCIN IN THE BLUE AND GOLD MACAW (ARA ARARAUNA) AFTER INTRAVENOUS AND ORAL ADMINISTRATION , 2005, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[16]  P. Marín,et al.  Pharmacokinetics of azithromycin after i.v. and i.m. administration to sheep. , 2005, Journal of veterinary pharmacology and therapeutics.

[17]  M W Dunne,et al.  Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. , 2005, The Journal of antimicrobial chemotherapy.

[18]  B. Lawson,et al.  Garden bird health , 2005, Veterinary Record.

[19]  D. Touw,et al.  Quantitative determination of azithromycin in plasma, blood and isolated neutrophils by liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl-chloride and fluorescence detection. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  G. Amsden,et al.  Single-Dose Azithromycin for Respiratory Tract Infections , 2004, The Annals of pharmacotherapy.

[21]  J. Blumer,et al.  Rationale for single and high dose treatment regimens with azithromycin , 2004, The Pediatric infectious disease journal.

[22]  P. Tulkens,et al.  Macrolides: pharmacokinetics and pharmacodynamics. , 2001, International journal of antimicrobial agents.

[23]  Daniel J. Holder.  COMMENTS ON NEDELMAN AND JIA'S EXTENSION OF SATTERTHWAITE'S APPROXIMATION APPLIED TO PHARMACOKINETICS , 2001, Journal of biopharmaceutical statistics.

[24]  B. Olsen,et al.  Feral pigeons as carriers of Cryptococcus laurentii, Cryptococcus uniguttulatus and Debaryomyces hansenii. , 1999, Medical mycology.

[25]  M. Donati,et al.  Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. , 1999, The Journal of antimicrobial chemotherapy.

[26]  E. Scanziani,et al.  Epidemiological and Environmental Investigations ofLegionella pneumophila Infection in Cattle and Case Report of Fatal Pneumonia in a Calf , 1998, Journal of Clinical Microbiology.

[27]  F. Soriano,et al.  In Vitro Susceptibilities of Aerobic and Facultative Non-Spore-Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials , 1998, Antimicrobial Agents and Chemotherapy.

[28]  G. Foulds,et al.  Disposition of oral azithromycin in humans * , 1997, Clinical pharmacology and therapeutics.

[29]  C. Nightingale.  Pharmacokinetics and pharmacodynamics of newer macrolides. , 1997, The Pediatric infectious disease journal.

[30]  W. Craig.  Antimicrobial resistance issues of the future. , 1996, Diagnostic microbiology and infectious disease.

[31]  R. Gladue,et al.  Intracellular accumulation of azithromycin by cultured human fibroblasts , 1990, Antimicrobial Agents and Chemotherapy.

[32]  R. Isaacson,et al.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection , 1989, Antimicrobial Agents and Chemotherapy.

[33]  Jinli Wang,et al.  In vitro synergistic effect of baicalin with azithromycin against Staphylococcus saprophyticus isolated from francolins with ophthalmia , 2019, Poultry science.

[34]  K. Abo-El-Sooud,et al.  Pharmacokinetics and bioavailability of azithromycin following intramuscular and oral administrations in broiler chickens , 2012 .

[35]  J. Blumer.  Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. , 2005, International journal of antimicrobial agents.

[36]  ZITHROMAX ® ( azithromycin tablets ) and ( azithromycin for oral suspension ) , 2004 .

[37]  K. Yamaguchi.  Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate , 2001, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[38]  T. Wichelhaus,et al.  New Colorimetric Microdilution Method for In Vitro Susceptibility Testing of Borrelia burgdorferi Against Antimicrobial Substances , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[39]  J. Nedelman,et al.  An extension of Satterthwaite's approximation applied to pharmacokinetics. , 1998, Journal of biopharmaceutical statistics.